Company intelligence / Profile preview

Brink Biologics

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Brink Biologics commercializes the NK-92 cell line and CD16 derivatives for functional immunoassays, providing reliable tools for antibody-dependent cellular cytotoxicity (ADCC) and related testing, widely used across pharma and biologics development for activity, immunogenicity, and batch release studies[1][2][3][4].

Therapeutic areas: Other
Modalities: Cell line (specifically: NK-92 cell line)Cell-based assay
Industry: Non-Drug Biotech

Partnerships

Fresenius Kabi SwissBioSim GmbH (licensed Neukopanel NK cell platform)[1][4]Large pharmaceuticals and biotechnology companies (customers/users)[1]

Beyond the preview

Go deeper on Brink Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brink Biologics.

Explore the full profile